FGFR4 and dyskeratosis congenita: Since FGFR4 p.G388R was the only genetic variant shared by long-lasting DC patients, its prognostic impact on survival of the entire clinical cohort of metastatic CRC patients treated with TAS-102 was studied (Fig. 3).